Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.69 |
| ▸ | ECE1 | P42892 | 12/20 | 0.61 |
| ▸ | MME | P08473 | 11/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP14 | P50281 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613489 | 1.00 | ACE2 (0.69) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL24991304 | 1.00 | ACE2 (0.69) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL7613146 | 1.00 | ACE2 (0.69) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL6923615 | 0.92 | ACE2 (0.58) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL7619363 | 0.91 | ACE2 (0.68) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL7619360 | 0.91 | ACE2 (0.68) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL7620840 | 0.91 | ACE2 (0.68) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL7615297 | 0.88 | ECE1 (0.76) | ACE2ECE1MME | |
| SCHEMBL6928872 | 0.88 | ACE2 (0.66) | ACE2ECE1MMEMMP2MMP9 | |
| SCHEMBL7611003 | 0.85 | ANPEP (0.54) | ACE2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
| US-8703747-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS | 2011-05-26 | — | — | US | disclosed |
| EP-1073664-B1 | (ALPHA-AMINOPHOSPHINO) PEPTIDESDERIVATIVE AND COMPOSITIONS CONTAINING SAME | INST NAT SANTE RECH MED (FR) | 2002-10-23 | — | — | EP | disclosed |
| EP-1009750-B1 | NOVEL (ALPHA-AMINOPHOSPHINO) PEPTIDE DERIVATIVES, METHOD FOR MAKING SAME AND THERAPEUTIC APPLICATIONS THEREOF | INST NAT SANTE RECH MED (FR) | 2002-07-31 | — | — | EP | disclosed |
| US-6391866-B1 | ANALGESICS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124601-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | ACE2 3562/4885ECE1 4157/4885MME 3670/4885 |
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | ACE2 3454/4885ECE1 4097/4885MME 3490/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | ACE2 3454/4885ECE1 4097/4885MME 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.